K. Siobhan Barone Ph.D., Thomas More University
Christine BrainsonPh.D., University of Kentucky College of Medicine, Toxicology and Cancer Biology
Jeremy Graff, Ph.D., BioThera Pharmaceuticals
Julia Carter, Ph.D.,Wood Hudson Cancer Research Lab
This event was virtual - The Kentucky Academy of Science co-hosted this event with the Wood Hudson Cancer Research Lab. Panelist Bios: Christine Fillmore Brainson, Ph.D.
In October 2016, Dr. Brainson joined the University of Kentucky (UK) Toxicology and Cancer Biology department, where her laboratory integrates studies of epigenetic programs, stem cell biology, and precision cancer medicine for lung cancer. Dr. Brainson trained in cancer, epigenetic and stem cell biology at the Dana-Farber Cancer Institute with Dr. Charles Roberts, at Tufts University with Dr. Charlotte Kuperwasser, and at Boston Children’s Hospital and Harvard Genetics with Dr. Carla Kim. At UK, she has joined an outstanding group of experts with whom she will continue studies of lung cancer subtypes, genotypes and drug responses. Her studies funded through the National Cancer Institute, American Cancer Society and American Association for Cancer Research involve understanding how epigenetics can influence tumor biology and therapy responses. Dr. Brainson’s recently funded R01 grant will explore the exciting possible synergy between EZH2 inhibition and the PD1/PD-L1 immune checkpoint inhibitors. In addition to this work, the lab is exploring how EZH2 inhibitors can be used in other novel drug combinations, the role of EZH2 in chronic obstructive pulmonary disease and how dietary methionine changes lung cancer epigenetics and therapy response. More about her lab: http://fillmorebrainsonlab.uky.edu/; Article on immunotherapy work: https://www.v.org/2019/under-the-microscope-targeting-lung-cancer-with-a-one-two-punch/
Dr. K. Siobhan Barone, Ph D.
K. Siobhan Barone is currently a Professor in the Department of Biological Sciences at Thomas More University. Having completed her Ph.D. degree in Microbiology at Miami University (Oxford, Ohio), she assumed a post-doctoral fellowship position for three years at the University of Cincinnati Medical Center. For the past several years, she has taught the first semester of General Biology for biology majors as well as Immunology, Microbiology and Biochemistry for upper classmen. In addition, she is the premedical advisor and the faculty advisor for the premedical society. Dr. Barone’s primary research interest is in Immunology and she has performed NIH sponsored research in that field with Thomas More University students. This research resulted in presentations at national conferences, such as the American Association of Immunologists (AAI) and the Autumn Immunology Conferences, as well as two peer-reviewed publications.
Jeremy R, Graff, Ph. D.
Jeremy Graff is a graduate of the University of Kentucky. He serves as Chief Scientific Officer of IMV, Inc. IMV Inc is a clinical-stage biopharmaceutical company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. He has spent 20 years of his career in Big Pharma (Eli Lilly and Company) and Biotech (Biothera Pharmaceuticals) focused on advancing novel cancer therapies and cancer immunotherapies through clinical development. His focus is on "Translational Science" as a means of enhancing the likelihood of clinical and regulatory success for novel cancer therapeutics and immunotherapeutics. He also serves on the board of the Wood Hudson Cancer Research Laboratory.
Julia H. Carter, Ph. D.
Julia Carter earned a PhD in Physiology from Rutgers University and did a post-doctoral fellowship in Cell Physiology at the Bureau of Biological Research at Rutgers. Julia is the President of the Wood Hudson Cancer Research Laboratory(co-hosting this program), a professional, independent, not-for-profit, publicly supported, research institute dedicated to the discovery of new knowledge regarding the causes, diagnosis, treatment, and prevention of cancer. Because the Laboratory is a not-for-profit enterprise, no organization or individual profits financially from its operation, and all discoveries resulting from ongoing research are freely given to the scientific and medical community through promptly reported peer-reviewed publications.Wood Hudson's focus on three areas:
1. Study of clinical cases and experimental models of cancer to learn new methods of cancer prevention, diagnosis, prognosis, and treatment
2. Study of environmental causes of cancer, particularly food and drinking water chemicals
3. Provision of training and hands-on research for undergraduate students through its Undergraduate Research Education Program (UREP).
Research at Wood Hudson Cancer Research Lab, now in it's 40th year, has been supported by long-term (16+) year research collaborations with academia, industry and government agencies as well as by numerous local, regional and national foundations. This research has been published in national and international peer reviewed publications.